Abstract Number: 0911 • ACR Convergence 2021
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with active axial spondyloarthritis (AxSpA) despite treatment with nonsteroidal anti-inflammatory drugs. The objective of…Abstract Number: 1093 • ACR Convergence 2021
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…Abstract Number: 1922 • ACR Convergence 2021
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…Abstract Number: 0065 • ACR Convergence 2021
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…Abstract Number: 0369 • ACR Convergence 2021
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…Abstract Number: 0820 • ACR Convergence 2021
The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, an adalimumab (ADL) biosimilar, received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I…Abstract Number: 0912 • ACR Convergence 2021
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study
Background/Purpose: The GO-ALIVE study assessed efficacy and safety of intravenous golimumab (IV GLM) in patients with ankylosing spondylitis (AS).1,2 In this post hoc analysis, we…Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…Abstract Number: 0066 • ACR Convergence 2021
Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
Background/Purpose: The mechanism by which HLA-B27 induces Ankylosing Spondylitis (AS) and related disease is unknown, but a leading hypothesis is that it presents ‘arthritogenic epitopes’…Abstract Number: 0372 • ACR Convergence 2021
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…Abstract Number: 0918 • ACR Convergence 2021
Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is effective in patients with radiographic axial spondyloarthritis (rad-axSpA). Assessment in SpondyloArthritis International Society (ASAS) 40 response – the…Abstract Number: 1305 • ACR Convergence 2021
Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study
Background/Purpose: Previous research in axial spondyloarthropathy(axSpA) has shown this population to have a high prevalence of depression. This co-morbidity has been previously shown to impact…Abstract Number: 0067 • ACR Convergence 2021
Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
Background/Purpose: Susceptibility to ankylosing spondylitis (AS) is known to be highly influenced by genetic factors, with heritability assessed in twins of >90%, with >115 genetic…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 62
- Next Page »